The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 23, 2019
Filed:
Mar. 14, 2017
Applicant:
Oryzon Genomics, S.a., Madrid, ES;
Inventors:
Mark D. Demario, New York, NY (US);
Tamara Maes, CornellĂ de Llobregat, ES;
William E. Pierceall, New York, NY (US);
Fiona Mack, New York, NY (US);
Serena Lunardi, CornellĂ de Llobregat, ES;
Assignee:
Oryzon Genomics, S.A., Madrid, ES;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/135 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61K 31/4402 (2006.01); A61K 31/47 (2006.01); A61K 31/52 (2006.01); A61K 31/404 (2006.01); A61K 31/635 (2006.01); A61K 31/167 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 31/4745 (2006.01); A61K 31/12 (2006.01); A61K 31/19 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/4045 (2006.01); A61K 31/475 (2006.01); A61K 31/495 (2006.01); A61K 31/519 (2006.01); A61K 31/555 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01);
U.S. Cl.
CPC ...
A61K 31/135 (2013.01); A61K 31/12 (2013.01); A61K 31/167 (2013.01); A61K 31/19 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/404 (2013.01); A61K 31/4045 (2013.01); A61K 31/4402 (2013.01); A61K 31/4545 (2013.01); A61K 31/47 (2013.01); A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/555 (2013.01); A61K 31/635 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01);
Abstract
The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).